98%
921
2 minutes
20
Pneumococcal disease (PD) caused by () continues to be a global public health concern. Monitoring the prevalence and shift of serotypes causing PD is critical for vaccination and local policies for PD management. A systematic review of published work on pneumococcal serotype distribution in the Chinese Mainland from January 1997 to July 2023 was conducted. The literature was searched in Medline, Embase, the Cochrane Library, Web of Science, CNKI, and Wanfang. Distribution of the serogroups/serotypes was presented as count and proportion. Pooled distributions were calculated using a double arcsine transformation. Subgroup analyses were performed according to isolate location, strain source, patient age, period, and clinical manifestation. In total 36,477 isolates in 159 studies were included. In the Chinese Mainland, the highest proportion of in PD was serotype 19F, followed by 19A, 23F, 14 and 6B. Serotype 19F was the most predominant circulating serotype through all time periods. PD cases caused by non-vaccine serotypes showed a significant increase after 2019. In summary, from 1997 to 2023, the top 10 prevalent serotypes causing PD in the Chinese Mainland were 19F, 19A, 6, 23F, 14, 6B, 6A, 3, 15B, and 9 V. Although the distribution of serotypes varied according to the subgroups, the increase in non-vaccine serotypes (e.g. 15A), and diversity distribution of serotypes 6A and 3 in different age groups should not be ignored.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622625 | PMC |
http://dx.doi.org/10.1080/21645515.2024.2416763 | DOI Listing |
Med Phys
September 2025
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Background: Dual-energy computed tomography (DECT) enhances material differentiation by leveraging energy-dependent attenuation properties particularly for carbon ion therapy. Accurate estimation of tissue elemental composition via DECT can improve quantification of physical and biological doses.
Objective: This study proposed a novel machine-learning-based DECT (ML-DECT) method to predict the physical density and mass ratios of H, C, N, O, P, and Ca.
Child Psychiatry Hum Dev
September 2025
Department of Psychology, University of California, Los Angeles, CA, USA.
Youth anxiety and depression are rising rapidly worldwide, highlighting the need for efficient school-based assessment tools across sociocultural contexts. The Revised Child Anxiety and Depression Scale (RCADS) is one of the most widely used screening measures, with demonstrated cross-cultural applicability. However, its psychometric properties have rarely been evaluated in Chinese populations.
View Article and Find Full Text PDFFront Psychol
August 2025
School of Mathematical Sciences, East China Normal University, Shanghai, China.
Introduction: This study explored the relationship between cultural values, goal orientation, and mathematics achievement in mainland China.
Methods: Structural equation modelling was used to analyze data collected from 1,004 first-year students of four majors in higher vocational colleges. This study adopted a four-dimensional goal orientation, including achievement (i.
Front Public Health
September 2025
School of Physical Education, Huaqiao University, Quanzhou, China.
Background: This study aims to analyze the status of sexual behavior and its influencing factors among first-year undergraduate students in Chinese overseas Chinese schools, providing scientific evidence for university sexual health education and public health interventions. It also explores sexual behavior patterns and prevention strategies in a multicultural context.
Methods: A cluster sampling method was employed to conduct a questionnaire survey among the 2024 cohort of freshmen at Huaqiao University ( = 4,892) in October 2024.
Front Oncol
August 2025
Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Introduction: In mainland China, trastuzumab deruxtecan was first authorized in February 2023 as a monotherapy for the treatment of patients with HER-2-positive adult breast cancer who were either unresectable or had metastasized after receiving one or more anti-HER-2 treatments. In July 2023, trastuzumab deruxtecan was approved for the treatment of patients with metastatic disease who had undergone at least one previous systemic therapy, as well as those with unresectable or metastatic adult breast cancer who had low expression of HER-2 and who had experienced a relapse within six months of finishing adjuvant chemotherapy.
Methods: The study included seven participants with HER-2 low expression breast cancer and eighteen participants with HER-2-positive advanced breast cancer from six study centers in Shandong Province, China.